Don't think this is right Doc, Gemini says those 0.5 CDR G patients are usually seen as stage 1 or 2 AD rather than stage 3 so is indeed relavant for the guidance as early stage. I doubt Anavex would have got that wrong they literally have mentioned the guidance in the PR. Almost two thirds of their trial were this early stage. They passed CDR-SB anyway with low p value too either way.
Market Data 
Markets 
AI
